Application of a Novel Microtitre Plate-Based Assay for the Discovery of New Inhibitors of DNA Gyrase and DNA Topoisomerase VI

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Taylor, James A ^a,b   Mitchenall, Lesley A ^a   Rejzek, Martin ^a   Field, Robert A ^a   Maxwell, Anthony ^a  

^a JOHN INNES CENTRE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; AMINOACRIDINE; AMSACRINE; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE VI; DNA TOPOISOMERASE VI INHIBITOR; GATIFLOXACIN; GYRASE INHIBITOR; HEXYLRESORCINOL; LEVOFLOXACIN; LOMEFLOXACIN; MEPACRINE; MITOXANTRONE; MOXIFLOXACIN; NATURAL PRODUCT; NORFLOXACIN; NOVOBIOCIN; OFLOXACIN; PEFLOXACIN; PURPURIN; SURAFLOXACIN; SURAMIN; UNCLASSIFIED DRUG;

ARABIDOPSIS; ARTICLE; ASSAY; CONTROLLED STUDY; DNA CLEAVAGE; DRUG IDENTIFICATION; DRUG SCREENING; ESCHERICHIA COLI; GROWTH INHIBITION; IC 50; METHANOSARCINA MAZEI; MICROTITER PLATE BASED ASSAY; MYCOBACTERIUM SMEGMATIS; NONHUMAN; SULFOLOBUS SHIBATAE;

ANTHRAQUINONES; ARABIDOPSIS; ARCHAEAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; HEXYLRESORCINOL; METHANOSARCINA; MITOXANTRONE; QUINACRINE; SULFOLOBUS; SURAMIN; TOPOISOMERASE INHIBITORS;

EID: 84874468435     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058010     Document Type: Article

References (83)

1. Woodford N, Livermore DM, (2009) Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 59Suppl 1: S4-16.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NP, et al. (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8: 272-280.
3. Lew W, Pai M, Oxlade O, Martin D, Menzies D, (2008) Initial drug resistance and tuberculosis treatment outcomes: Systematic review and meta-analysis. Annals of Internal Medicine 149: 123-134.
4. Rice LB, (2003) Do we really need new anti-infective drugs? Curr Opin Pharmacol 3: 459-463.
5. Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, et al. (2010) Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 15: 19688.
6. Flament-Saillour M, Robert J, Jarlier V, Grosset J, (1999) Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160: 587-593.
7. Cooper MA, Shlaes D, (2011) Fix the antibiotics pipeline. Nature 472: 32.
8. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
9. Pommier Y, Leo E, Zhang H, Marchand C, (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17: 421-433.
10. Tse-Dinh YC, (2007) Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets 7: 3-9.
11. Bradbury BJ, Pucci MJ, (2008) Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 8: 574-581.
12. Collin F, Karkare S, Maxwell A, (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92: 479-497.
13. Bates AD, Maxwell A (2005) DNA Topology. Oxford: Oxford University Press.
14. Berger JM, Gamblin SJ, Harrison SC, Wang JC, (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232.
15. Stewart L, Redinbo MR, Qiu X, Hol WG, et al. (1998) A Model for the Mechanism of Human Topoisomerase I. Science. 279: 1534-1541.
16. Lima CD, Wang JC, Mondragon A, (1994) Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I. Nature. 367: 138-146.
17. Sander M, Hsieh T, (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J Biol Chem 258: 8421-8428.
18. Liu LF, Liu CC, Alberts BM, (1980) Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19: 697-707.
19. Wang JC, (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Quarterly Reviews of Biophysics 31: 107-144.
20. Bates AD, Maxwell A, (2007) Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry 46: 7929-7941.
21. Nollmann M, Crisona NJ, Arimondo PB, (2007) Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 89: 490-499.
22. Champoux JJ, (2001) DNA topoisomerases: Structure, function, and mechanism. Annual Review of Biochemistry 70: 369-413.
23. Bates AD, Berger JM, Maxwell A, (2011) The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks. Nucleic Acids Res 39: 6327-6339.
24. Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JI, (1977) Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 74: 4772-4776.
25. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR, (1977) Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proceedings of the National Academy of Sciences of the United States of America 74: 4767-4771.
26. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, et al. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466: 935-940.
27. Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, et al. (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS ONE 5: e11338.
28. Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 16: 667-669.
29. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, et al. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17: 1152-1153.
30. Maxwell A, Lawson DM, (2003) The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 3: 283-303.
31. Maxwell A, (1993) The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 9: 681-686.
32. Heide L, Li S-M (2002) Aminocoumarin antibiotics. In: Rubio F, editor. Microbial Secondary Metabolites: Biosynthesis, Genetics and Regulation: Research Signpost.
33. Flatman RH, Howells AJ, Heide L, Fiedler HP, Maxwell A, (2005) Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob Agents Chemother 49: 1093-1100.
34. Edwards MJ, Flatman RH, Mitchenall LA, Stevenson CE, Le TB, et al. (2009) A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 326: 1415-1418.
35. Edwards MJ, Williams MA, Maxwell A, McKay AR, (2011) Mass spectrometry reveals that the antibiotic simocyclinone D8 binds to DNA gyrase in a "bent-over" conformation: evidence of positive cooperativity in binding. Biochemistry 50: 3432-3440.
36. Corbett KD, Benedetti P, Berger JM, (2007) Holoenzyme assembly and ATP-mediated conformational dynamics of topoisomerase VI. Nature Structural & Molecular Biology 14: 611-619.
37. Graille M, Cladiere L, Durand D, Lecointe F, Gadelle D, et al. (2008) Crystal structure of an intact type II DNA topoisomerase: insights into DNA transfer mechanisms. Structure 16: 360-370.
38. Buhler C, Lebbink JH, Bocs C, Ladenstein R, Forterre P, (2001) DNA topoisomerase VI generates ATP-dependent double-strand breaks with two-nucleotide overhangs. J Biol Chem 276: 37215-37222.
39. Hartung F, Angelis KJ, Meister A, Schubert I, Melzer M, et al. (2002) An archaebacterial topoisomerase homolog not present in other eukaryotes is indispensable for cell proliferation of plants. Curr Biol 12: 1787-1791.
40. Sugimoto-Shirasu K, Stacey NJ, Corsar J, Roberts K, McCann MC, (2002) DNA topoisomerase VI is essential for endoreduplication in Arabidopsis. Curr Biol 12: 1782-1786.
41. Hartung F, Puchta H, (2000) Molecular characterisation of two paralogous SPO11 homologues in Arabidopsis thaliana. Nucleic Acids Res 28: 1548-1554.
42. Aravind L, Iyer LM, Wellems TE, Miller LH, (2003) Plasmodium biology: genomic gleanings. Cell 115: 771-785.
43. Gadelle D, Graille M, Forterre P, (2006) The HSP90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase. Biochemical Pharmacology 72: 1207-1216.
44. Bergerat A, Gadelle D, Forterre P, (1994) Purification of a DNA topoisomerase II from the hyperthermophilic archaeon Sulfolobus shibatae. A thermostable enzyme with both bacterial and eucaryal features. Journal of Biological Chemistry 269: 27663-27669.
45. Taylor JA, Burton NP, Maxwell A, (2012) High-throughput microtitre plate-based assay for DNA topoisomerases. Methods Mol Biol 815: 229-239.
46. Maxwell A, Burton NP, O'Hagan N, (2006) High-throughput assays for DNA gyrase and other topoisomerases. Nucleic Acids Res 34: e104.
47. Burrell MR, Burton NP, Maxwell A, (2010) A high-throughput assay for DNA topoisomerases and other enzymes, based on DNA triplex formation. Methods Mol Biol 613: 257-266.
48. Chong CR, Sullivan DJ Jr, (2007) New uses for old drugs. Nature 448: 645-646.
49. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
50. Harvey AL, (2007) Natural products as a screening resource. Curr Opin Chem Biol 11: 480-484.
51. Zhang JH, Chung TD, Oldenburg KR, (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
52. Funatsuki K, Tanaka R, Inagaki S, Konno H, Katoh K, et al. (1998) Quinolone-resistant mutations of DNA gyrase increase sensitivity to acriflavine. Biol Pharm Bull 21: 667-672.
53. Buhler C, Gadelle D, Forterre P, Wang JC, Bergerat A, (1998) Reconstitution of DNA topoisomerase VI of the thermophilic archaeon Sulfolobus shibatae from subunits separately overexpressed in Escherichia coli. Nucleic Acids Res 26: 5157-5162.
54. Finlay GJ, Atwell GJ, Baguley BC, (1999) Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions. Oncol Res 11: 249-254.
55. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, et al. (1992) Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proceedings of the National Academy of Sciences of the United States of America 89: 3025-3029.
56. Chauhan PM, Srivastava SK, (2001) Present trends and future strategy in chemotherapy of malaria. Curr Med Chem 8: 1535-1542.
57. Gadelle D, Bocs C, Graille M, Forterre P, (2005) Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol. Nucleic Acids Research 33: 2310-2317.
58. Smith PJ, Morgan SA, Fox ME, Watson JV, (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochemical Pharmacology 40: 2069-2078.
59. Schrappe M, (2010) Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. Lancet 376: 1968-1970.
60. Stein CA, (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Research 53: 2239-2248.
61. Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, et al. (2008) The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemotherapy and Pharmacology 61: 739-749.
62. Reece RJ, Maxwell A, (1989) Tryptic fragments of the Escherichia coli DNA gyrase A protein. J Biol Chem 264: 19648-19653.
63. Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, et al (1997) The complete genome sequence of Escherichia coli K-12. Science 277: 1453-1474.
64. Ruiz N, Falcone B, Kahne D, Silhavy TJ, (2005) Chemical conditionality: a genetic strategy to probe organelle assembly. Cell 121: 307-317.
65. Ruiz N, Kahne D, Silhavy TJ, (2006) Advances in understanding bacterial outer-membrane biogenesis. Nature Reviews Microbiology 4: 57-66.
66. Sugimoto-Shirasu K, Roberts GR, Stacey NJ, McCann MC, Maxwell A, et al. (2005) RHL1 is an essential component of the plant DNA topoisomerase VI complex and is required for ploidy-dependent cell growth. Proc Natl Acad Sci U S A 102: 18736-18741.
67. Sugimoto-Shirasu K, Roberts K, (2003) "Big it up": endoreduplication and cell-size control in plants. Curr Opin Plant Biol 6: 544-553.
68. Bergerat A, de Massy B, Gadelle D, Varoutas P-C, Nicolas A, et al. (1997) An atypical topoisomerase II from archaea with implications for meiotic recombination. Nature 386: 414-417.
69. Mah TF, O'Toole GA, (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends in Microbiology 9: 34-39.
70. Finlay GJ, Wilson WR, Baguley BC, (1989) Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur J Cancer Clin Oncol 25: 1695-1701.
71. Nelson EM, Tewey KM, Liu LF, (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 81: 1361-1365.
72. Thielmann HW, Popanda O, Edler L, (1991) The effects of inhibitors of topoisomerase II and quinacrine on ultraviolet-light-induced DNA incision in normal and xeroderma pigmentosum fibroblasts. J Cancer Res Clin Oncol 117: 19-26.
73. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, et al. (1998) Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother 42: 2731-2738.
74. Sturm A, Heussler V, (2007) Live and let die: manipulation of host hepatocytes by exoerythrocytic Plasmodium parasites. Med Microbiol Immunol 196: 127-133.
75. Figgitt D, Denny W, Chavalitshewinkoon P, Wilairat P, Ralph R, (1992) In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob Agents Chemother 36: 1644-1647.
76. Shaner DL, Lindenmeyer RB, Ostlie MH (2011) What have the mechanisms of resistance to glyphosate taught us? Pest Manag Sci.
77. Nierman MM, (1961) Akrinol, a new topical anti-infective agent. J Indiana State Med Assoc 54: 614-617.
78. Kraal JH, Hussain AA, Gregorio SB, Akaho E, (1979) Exposure time and the effect of hexylresorcinol on bacterial aggregates. J Dent Res 58: 2125-2131.
79. Maxwell A, Howells AJ (1999) Overexpression and purification of bacterial DNA gyrase. In: Bjornsti M-A, Osheroff N, editors. DNA Topoisomerase Protocols I DNA Topology and Enzymes. Totowa, New Jersey: Humana Press. 135-144.
80. Jordan KL, Evans DL, Hall DJ, (1999) Purification of supercoiled plasmid DNA. Methods in Molecular Biology 94: 41-49.
81. Ali JA, Jackson AP, Howells AJ, Maxwell A, (1993) The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 32: 2717-2724.
82. Pierrat OA, Maxwell A, (2005) Evidence for the role of DNA strand passage in the mechanism of action of microcin B17 on DNA gyrase. Biochemistry 44: 4204-4215.
83. Murashige T, Skoog F (1962) A Revised Medium for Rapid Growth and Bio Assays with Tobacco Tissue Cultures. Physiologia Plantarum 15: 473-&.